Address And Details

2005 Market St. , Philadelphia, PA 19103
Fund Manager Susan Regan
Manager Tenure 3 Years 5 Months

Strategy And Objective

To seek to provide current income consistent with preservation of capital. Ivy Corporate Bond Fund seeks to achieve its objective by investing, under normal circumstances, at least 80% of its net assets in corporate bonds (also referred to as corporate debt securities or fixed-income securities ). For this purpose, corporate bonds includes any debt security issued by a domestic or foreign company with an initial maturity greater than one year. The Fund invests primarily in investment-grade debt securities (including bonds rated BBB- or higher by S&P Global Ratings, a division of S&P Global Inc. (S&P), or comparably rated by another nationally recognized statistical rating organization (NRSRO) or, if unrated, determined by Ivy Investment Management Company(IICO) to be of comparable quality). The Fund may invest up to 20% of its net assets in other types of debt securities, including mortgage-backed securities, debt securities issued or guaranteed by the U.S. government or any of its agencies or instrumentalities (U.S. government securities) and other asset-backed securities. Certain of the mortgage-backed securities in which the Fund may invest are not backed by the full faith and credit of the U.S. government and, like other asset-backed securities in which the Fund may invest,may be backed only by the pool of assets pledged as security for the transaction. The Fund has no limitations regarding the duration or dollar-weighted average of its holdings,may invest in debt securities with varying maturities and can invest in debt securities issued by both domestic and foreign companies, in a variety of sectors and industries. The Fund may invest significantly in debt securities payable from the same sector.

Net Asset Value

as of 5:48 PM ET 09/17/2021

Performance

  • 1 Week
  • -0.15%
  • 1 Month
  • 0.00%
  • 3 Months
  • +1.07%
  • 1 Yr Return
  • -4.76%
  • 5 Yr Return
  • n/a

Equity Sector Breakdown

ConsumerDurables n/a
Energy n/a
Finance n/a
Health n/a
IndustrialCyclical n/a
NonDurables n/a
RetailTrade n/a
Services n/a
Technology n/a
Utilities n/a

Asset Allocation

Asset Type % Of Allocation
Bonds 96.89%
Cash 1.97%
Other 1.14%
Stocks 0.00%
Preferred 0.00%
Convertible 0.00%
ForeignStocks 0.00%
ForeignBonds 0.00%
ForeignHedged 0.00%
Total Net Assets 450.00 M

Risk Measures

Criteria 3 Years 5 Years 10 Years
Alpha -0.07 0.54 0.08
Beta 1.51 1.37 1.25
R Squared 0.62 0.65 0.69
Std Deviation 6.61 5.48 4.43
Sharpe Ratio 1.00 0.62 n/a

Purchase Information

as of 6:05 PM ET 09/16/2021
Minimum Initial $0
Minimum Additional $0
Minimum Initial IRA $0

Performance

Timeframe Average Annual Current Performance Monthly As Of 08/31/2021 Average Annual Current Performance Quarterly As Of 05/31/2021 Avg Annual Current Performance Monthly As Of 08/31/2021 Avg Annual Current Performance Quarterly As Of 05/31/2021
1 Year
  • +2.84%
  • +4.01%
+2.84% +4.01%
3 Year
  • +7.56%
  • +6.84%
+7.56% +6.84%
10 Year
  • +3.89%
  • +3.87%
+3.89% +3.87%
Life Of Fund
  • +5.10%
  • +5.04%
+5.10% +5.04%

Top 10 Holdings

Symbol Company Name % Of Assets
n/a

Recent Articles from TheStreet

Nasdaq-listed Chinese Electric Carmaker Li Auto Apologises For Passing Off Recall Of 10,469 Li ONEs As 'upgrade' Offer

Chinese EV Maker Li Cuts Delivery Forecast, Shares Fall

Li trims its forecast to 24,500 vehicle deliveries for the third quarter from 25,000 to 26,000.

Toys 'R' Us Sells FAO Schwarz as it Reveals Further Debt Refinancing Plans

Toymakers Facing Holiday Challenge Due to Supply-Chain Issues

Supply-chain issues could make this Christmas season more challenging than normal for toymakers, a media report says.

AstraZeneca Takeover Chatter Bubbles Up Again After Massive Drug Trial Disappointment

AstraZeneca Stock Rises on Progress With Breast-Cancer Treatment

AstraZeneca's breast-cancer treatment reduced the risk of disease progression or death by 72% vs. a currently approved treatment.

Twitter Blue Lead

Twitter to Pay $810M to Settle Holder Suit Over User Engagement

Twitter's payment would settle a shareholder lawsuit that the company misled investors about its user engagement totals.

Starboard Takes Stake in CVS Health Corp.: Report

CVS to Add 25,000 Workers Ahead of Flu Season, Covid Booster Shots

Pharmacy giant CVS plans to add 25,000 ahead of flu season and coronavirus-related vaccinations.

Chinese Investors Mock Asset Managers And Offer Advice On Stock Picks For Cautious Approach To Renewables Sector

Stocks May Drop 20% as Stimulus Eases, Growth Slows: Morgan Stanley

Stocks could drop 20% as fiscal stimulus is withdrawn and economic growth slows, a Morgan Stanley strategist says.

Cryptocurrency Lead

Cryptocurrency Price Check: Bitcoin Tumbles on Evergrande Woes

Bitcoin and other cryptocurrencies are battered as China Evergrande Group struggles with bond obligations.

China Aims To Strengthen Its Semiconductor Supply Chain With New Standards Group That Includes Huawei, SMIC

Brooks Automation Stock Jumps on Plan to Sell Chip Solutions Unit for $3B

Brooks Automation is selling its chip solutions group and said it would no longer pursue splitting into two companies.

DR Horton, Verizon, HCA Holdings Top Analysts' Actions Monday

DR Horton Trims 2021 Sales Forecast Amid Supply Chain Disruptions

DR Horton said "significant disruptions in the supply chain ... along with tightness in the labor market" will lead to a modestly lower full-year sales forecast.

11. Colgate-Palmolive

Colgate-Palmolive Underappreciated, Deutsche Bank Says, Lifting to Buy

Colgate-Palmolive stock was upgraded to buy with an $86 price target at Deutsche Bank.